Kamada has just announced top-line results from the phase 1/2 open-label, single-arm, multi-center clinical trial of its anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG) treatment for coronavirus disease (COVID-19). The trial has been conducted in Israel as part of Kamada’s global collaboration with Kedrion Biopharma.
A total of 12 eligible patients (age 34-69) were enrolled and received the product. The effect of the treatment on neutralization activity is being further analyzed.
Eleven of the twelve patients recovered following receipt of the treatment. Seven patients were discharged from the hospital at or before day 5 post-treatment, and the remaining four patients were discharged by day 9.
Kamada is now utilizing plasma collected in the U.S. by KEDPLASMA to accelerate the manufacturing of the product, in anticipation of a potential expansion of the supply to Israel and possible demand from additional international markets.